ANALYSIS: Abbott/St Jude Merger Would Make Sense But Vascular Closure Potential Snag

Media reports of a potential $25bn bid by Abbott Laboratories for St Jude Medical, Inc., may have been promptly knocked down by Abbott, but that has not stopped shares of the cardiology firm rallying in the wake of the rumors.

More from Archive

More from Medtech Insight